These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 28744892)

  • 21. Bayesian predictive power for interim adaptation in seamless phase II/III trials where the endpoint is survival up to some specified timepoint.
    Schmidli H; Bretz F; Racine-Poon A
    Stat Med; 2007 Nov; 26(27):4925-38. PubMed ID: 17590875
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Optimal choice of the number of treatments to be included in a clinical trial.
    Stallard N; Posch M; Friede T; Koenig F; Brannath W
    Stat Med; 2009 Apr; 28(9):1321-38. PubMed ID: 19243083
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A comparison of methods for constructing confidence intervals after phase II/III clinical trials.
    Kimani PK; Todd S; Stallard N
    Biom J; 2014 Jan; 56(1):107-28. PubMed ID: 24173686
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A group-sequential design for clinical trials with treatment selection.
    Stallard N; Friede T
    Stat Med; 2008 Dec; 27(29):6209-27. PubMed ID: 18792085
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Performance of Fixed-Horizon, Look-Ahead Procedures Compared to Backward Induction in Bayesian Adaptive-Randomization Decision-Theoretic Clinical Trial Design.
    Lipsky AM; Lewis RJ
    Int J Biostat; 2019 Feb; 15(1):. PubMed ID: 30726189
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Screening designs for drug development.
    Rossell D; Müller P; Rosner GL
    Biostatistics; 2007 Jul; 8(3):595-608. PubMed ID: 17030589
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Designs for phase II trials allowing for a trade-off between response and toxicity.
    Conaway MR; Petroni GR
    Biometrics; 1996 Dec; 52(4):1375-86. PubMed ID: 8962459
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A Bayesian-adaptive decision-theoretic approach can reduce the sample sizes for multiarm exercise oncology trials.
    Buffart LM; Bassi A; Stuiver MM; Aaronson NK; Sonke GS; Berkhof J; van de Ven PM
    J Clin Epidemiol; 2023 Jul; 159():190-198. PubMed ID: 37245703
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A Bayesian Hybrid Adaptive Randomisation Design for Clinical Trials with Survival Outcomes.
    Moatti M; Chevret S; Zohar S; Rosenberger WF
    Methods Inf Med; 2016; 55(1):4-13. PubMed ID: 26404511
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Adaptive group sequential design for phase II clinical trials: a Bayesian decision theoretic approach.
    Chen Y; Smith BJ
    Stat Med; 2009 Nov; 28(27):3347-62. PubMed ID: 19725024
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Bayesian enrichment strategies for randomized discontinuation trials.
    Trippa L; Rosner GL; Müller P
    Biometrics; 2012 Mar; 68(1):203-11. PubMed ID: 21714780
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Adaptive designs with correlated test statistics.
    Götte H; Hommel G; Faldum A
    Stat Med; 2009 May; 28(10):1429-44. PubMed ID: 19226563
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Adaptive treatment allocation and selection in multi-arm clinical trials: a Bayesian perspective.
    Arjas E; Gasbarra D
    BMC Med Res Methodol; 2022 Feb; 22(1):50. PubMed ID: 35184731
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Sample size determination for phase II clinical trials based on Bayesian decision theory.
    Stallard N
    Biometrics; 1998 Mar; 54(1):279-94. PubMed ID: 9544522
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Incorporating historical information in biosimilar trials: Challenges and a hybrid Bayesian-frequentist approach.
    Mielke J; Schmidli H; Jones B
    Biom J; 2018 May; 60(3):564-582. PubMed ID: 29532950
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Group-sequential methods for adaptive seamless phase II/III clinical trials.
    Stallard N
    J Biopharm Stat; 2011 Jul; 21(4):787-801. PubMed ID: 21516569
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Meta-analysis of studies with bivariate binary outcomes: a marginal beta-binomial model approach.
    Chen Y; Hong C; Ning Y; Su X
    Stat Med; 2016 Jan; 35(1):21-40. PubMed ID: 26303591
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Decision-theoretic designs for pre-phase II screening trials in oncology.
    Stallard N; Thall PF
    Biometrics; 2001 Dec; 57(4):1089-95. PubMed ID: 11764248
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Decision-theoretic designs for phase II clinical trials allowing for competing studies.
    Stallard N
    Biometrics; 2003 Jun; 59(2):402-9. PubMed ID: 12926725
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A flexible multi-stage design for phase II oncology trials.
    Tan MT; Xiong X
    Pharm Stat; 2011; 10(4):369-73. PubMed ID: 22328328
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.